A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

van Meerbeeck, 2005, J Clin Oncol, 23, 6881, 10.1200/JCO.20005.14.589

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Zalcman, 2016, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, 387, 1405, 10.1016/S0140-6736(15)01238-6

Kindler, 2018, Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 36, 1343, 10.1200/JCO.2017.76.6394

Ceresoli, 2015, Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma, Cancer Treat Rev, 41, 853, 10.1016/j.ctrv.2015.10.006

Yap, 2017, Novel insights into mesothelioma biology and implications for therapy, Nat Rev Cancer, 17, 475, 10.1038/nrc.2017.42

Mansfield, 2014, B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis, J Thorac Oncol, 9, 1036, 10.1097/JTO.0000000000000177

Alley, 2017, Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial, Lancet Oncol, 18, 623, 10.1016/S1470-2045(17)30169-9

Curran, 1998, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145

Robins, 2000, Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests, Biometrics, 56, 779, 10.1111/j.0006-341X.2000.00779.x

Mok, 2019, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial, Lancet, 393, 1819, 10.1016/S0140-6736(18)32409-7

Kindler, 2017, OA 02.01 Randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma, J Thorac Oncol, 12, S1746, 10.1016/j.jtho.2017.09.328

Metaxas, 2018, Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma, J Thorac Oncol, 13, 1784, 10.1016/j.jtho.2018.08.007

Cheng, 2015, Response evaluation in mesothelioma: beyond RECIST, Lung Cancer, 90, 433, 10.1016/j.lungcan.2015.08.012

Hasan, 2014, Eur J Cancer, 50, 2771, 10.1016/j.ejca.2014.07.020

Okada, 2019, Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT), Clin Cancer Res, 25, 5485, 10.1158/1078-0432.CCR-19-0103

Quispel-Janssen, 2018, Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma, J Thorac Oncol, 13, 1569, 10.1016/j.jtho.2018.05.038

Bueno, 2016, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, 48, 407, 10.1038/ng.3520

Calabro, 2013, Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial, Lancet Oncol, 14, 1104, 10.1016/S1470-2045(13)70381-4

Calabro, 2015, Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study, Lancet Respir Med, 3, 301, 10.1016/S2213-2600(15)00092-2

Hassan, 2019, Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial, JAMA Oncol, 5, 351, 10.1001/jamaoncol.2018.5428

Scherpereel, 2019, Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol, 20, 239, 10.1016/S1470-2045(18)30765-4

Calabro, 2018, Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study, Lancet Respir Med, 6, 451, 10.1016/S2213-2600(18)30151-6

Disselhorst, 2019, Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial, Lancet Respir Med, 7, 260, 10.1016/S2213-2600(18)30420-X